Denmark's Genmab expands biotech collaboration with Janssen

COPENHAGEN Wed Dec 4, 2013 9:32am EST

Related Topics

COPENHAGEN (Reuters) - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.

Genmab said it will receive an initial payment of $2 million and potentially will be entitled to milestone and license payments of as much as $174 million to $219 million for each of ten additional programmes.

(Reporting by Teis Jensen; Editing by David Goodman)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.